• EdU Imaging Kits: Precision DNA Synthesis Measurement in Cel

  2026-04-12

  EdU Imaging Kits (HF488) deliver high-sensitivity, non-denaturing detection of DNA synthesis, enabling accurate cell proliferation quantification for translational research. Streamlined click chemistry workflows outperform BrdU assays, supporting advanced applications in biomarker validation, drug screening, and precision oncology.

• Redefining qPCR Precision for Translational Biomarker Discov

  2026-04-12

  This thought-leadership article explores the mechanistic and strategic value of HotStart™ Universal 2X FAST Green qPCR Master Mix (Rox) for translational researchers seeking to advance biomarker discovery and gene expression analysis. Integrating mechanistic insights, recent literature on AKTIP as a biomarker for fibrolamellar carcinoma, and expert protocol guidance, the article provides actionable recommendations and forward-looking perspectives for high-impact translational workflows.

• Tropifexor (LJN452): Advancing FXR Pathway and Barrier Resea

  2026-04-11

  Tropifexor (LJN452) sets a new standard for modulating the FXR signaling pathway in metabolic and intestinal epithelial barrier research. Leveraging robust nanomolar potency and validated workflows, this APExBIO product empowers precise, reproducible studies in both in vivo and organoid models.

• Azithromycin Applications: Advanced Macrolide Antibiotic Wor

  2026-04-11

  Azithromycin’s targeted inhibition of bacterial protein synthesis makes it indispensable for bacterial infection research, resistance profiling, and trypanosomosis animal models. This guide translates recent pharmacodynamic insights and robust protocol enhancements into actionable steps for maximizing experimental success and reproducibility.

• AZD3514: Practical Guidance for AR Downregulation Research

  2026-04-10

  AZD3514 is a potent androgen receptor downregulator suited for advanced prostate cancer research, particularly studies targeting AR signaling and antiandrogen therapy mechanisms. It is not intended for applications lacking AR pathway involvement or outside the context of defined prostate cancer models.

• AZD2461: Next-Generation PARP Inhibitor for Advanced Brea...

  2026-04-10

  Explore the unique advantages of AZD2461, a novel PARP inhibitor, in breast cancer research. This article delves into its molecular action, resistance-bypassing properties, and innovative experimental applications for DNA repair pathway modulation.

• Azithromycin: Macrolide Antibiotic Mechanisms & Research ...

  2026-04-09

  Azithromycin is a 15-membered macrolide antibiotic widely employed as a bacterial protein synthesis inhibitor in infection research. Its efficacy and specificity for the 50S ribosomal subunit underpin its utility for resistance screening and trypanosomosis models. APExBIO’s formulation offers benchmark reproducibility and meets stringent analytical and storage criteria.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Res...

  2026-04-08

  Azathramycin A stands out as a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, enabling precise protein synthesis inhibition studies and antibiotic resistance modeling. Its unique properties as an azithromycin degradation product empower researchers to dissect ribosomal mechanisms and optimize tuberculosis infection models with reproducible, high-specificity results.

• Lypressin Acetate: Advanced Insights into Vasopressin Rec...

  2026-04-08

  Explore the multifaceted science of Lypressin acetate, a potent vasopressin analog and G protein-coupled receptor agonist, as both a benchmark in antidiuretic hormone analog research and a promising SARS-CoV-2 RdRp inhibitor. This article delivers unique mechanistic depth, translational perspectives, and the latest breakthroughs beyond standard applications.

• Azathramycin A: Macrolide Ribosome Inhibitor for Tubercul...

  2026-04-07

  Azathramycin A is a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, providing a well-characterized pathway for bacterial protein synthesis inhibition. As a verified impurity and degradation product of Azithromycin, Azathramycin A enables precise, reproducible studies of antibiotic mechanisms and resistance in tuberculosis research.

• AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

  2026-04-07

  AZD0156 is a potent, highly selective ATM kinase inhibitor for cancer research, enabling precise dissection of the DNA damage response pathway. This small molecule from APExBIO offers sub-nanomolar potency and exceptional selectivity, facilitating studies in genomic stability and checkpoint control. Its unique solubility and storage profile support robust preclinical and translational research workflows.

• AZD2461: Redefining PARP Inhibition and Resistance in Bre...

  2026-04-06

  Explore the multifaceted role of AZD2461, a novel PARP inhibitor, in breast cancer research—highlighting its unique mechanisms in overcoming Pgp-mediated resistance, inducing G2-phase cell cycle arrest, and extending relapse-free survival. This in-depth analysis uncovers advanced strategies for DNA repair pathway modulation and resistance studies.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research

  2026-04-06

  AZD2461 is a next-generation poly (ADP-ribose) polymerase inhibitor with high specificity for PARP-1, demonstrating robust cytotoxicity in breast cancer cell lines and overcoming P-glycoprotein-mediated drug resistance. This dossier details its molecular mechanism, experimental benchmarks, and integration into advanced DNA repair and relapse prevention research workflows.

• Azathramycin A: Macrolide Ribosome Inhibitor for Tubercul...

  2026-04-05

  Azathramycin A is a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, providing a validated model for bacterial protein synthesis inhibition in tuberculosis research. As a major impurity of azithromycin, it is critical for antibiotic resistance and degradation pathway studies.

• Azithromycin (SKU B1398): Reliable Solutions for Bacteria...

  2026-04-04

  This article delivers a scenario-driven, evidence-based exploration of Azithromycin (SKU B1398) as a macrolide antibiotic for cell-based assays, resistance screening, and animal infection models. Researchers will find practical guidance grounded in quantitative data, comparative insights, and validated protocols, with a focus on experimental reproducibility and workflow integrity.

15217 records 1/1015 page Next 12345 下5页 Last page